Celltrion unit pays $330 million for Eli Lilly production facility, filing shows (updated)
23/09/2025 02:27
Adds Celltrion's statement SEOUL, Sept 23 (Reuters) - Celltrion Inc. 068270.KS said in a regulatory filing in South Korea on Tuesday its U.S. subsidiary has acquired Imclone Systems LLC from Eli Lilly in the United States for $330 million. In a statement, Celltrion said it aimed to complete the factory acquisition process by year-end in cooperation with its partner. After upgrades and expansions to the facility, both key products the company sells in the United States and future launches will be shielded early from U.S. tariff exposure. (Reporting by Jack Kim and Heekyong Yang; Editing by Clarence Fernandez) ((jack.kim@thomsonreuters.com; +822 6936 1455;))
Recent news on Celltrion
See all newsBrief: Celltrion Inc To Acquire 100 Billion Won Worth Of Own Shares
Brief: Celltrion Q1 Operating. Profit 322 Billion Won, Up 115% Y/Y
Brief: Celltrion To Cancel 100 Billion Won Treasury Shares
Brief: Celltrion Plans Phase 3 Clinical Trials For Keytruda Biosimilar With 220 Patients
Brief: Celltrion To Buy 100 Billion Won Of Own Shares